DOCSLIB.ORG

Cyddc Functions As a Cytoplasmic Cystine Reductase to Sensitize Escherichia Coli to Oxidative Stress and Aminoglycosides

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Cyddc Functions As a Cytoplasmic Cystine Reductase to Sensitize Escherichia Coli to Oxidative Stress and Aminoglycosides CydDC functions as a cytoplasmic cystine reductase to sensitize Escherichia coli to oxidative stress and aminoglycosides Alexander Mironova,b, Tatyana Sereginaa,b, Konstantin Shatalinc, Maxim Nagornykha, Rustem Shakulova, and Evgeny Nudlerc,d,1 aDepartment of Molecular Biology, Engelhardt Institute of Molecular Biology, Russian Academy of Science, 119991 Moscow, Russia; bCenter for Precision Genome Editing and Genetic Technologies for Biomedicine, Engelhardt Institute of Molecular Biology, Russian Academy of Sciences, 119991 Moscow, Russia; cDepartment of Biochemistry and Molecular Pharmacology, New York University School of Medicine, New York, NY 10016; and dHHMI, New York University School of Medicine, New York, NY 10016 Edited by James J. Collins, Massachusetts Institute of Technology, Boston, MA, and approved August 6, 2020 (received for review April 22, 2020) L-cysteine is the source of all bacterial sulfurous biomolecules. dependent manner (10, 13, 14). However, whether CydDC is However, the cytoplasmic level of L-cysteine must be tightly reg- involved in exporting L-cysteine or GSH to the periplasm of living ulated due to its propensity to reduce iron and drive damaging cells remains unknown, as is the mechanism by which this complex Fenton chemistry. It has been proposed that in Escherichia coli the maintains the cellular redox status. component of cytochrome bd-I terminal oxidase, the CydDC com- Because of its highly labile nature, dynamic distribution be- plex, shuttles excessive L-cysteine from the cytoplasm to the peri- tween cellular compartments, and overall low concentration, direct plasm, thereby maintaining redox homeostasis. Here, we provide and accurate measurement of intracellular L-cysteine has been evidence for an alternative function of CydDC by demonstrating highly challenging, leading to inconclusive and sometime contra- that the cydD phenotype, unlike that of the bona fide L-cysteine eamA tcyP. dictory results (3, 8). Recently, we demonstrated that the accumu- exporter , parallels that of the L-cystine importer Chro- E. coli mosomal induction of eamA, but not of cydDC, from a strong lation of L-cysteine in directly correlates with the level of enzymatically produced H2S (15). The sequential action of cyto- pLtetO-1 promoter (Ptet) leads to the increased level of extracellu- BIOCHEMISTRY lar L-cysteine, whereas induction of cydDC or tcyP causes the ac- plasmic aspartate aminotransferase (AspC) and 3-mercaptopyruvate cumulation of cytoplasmic L-cysteine. Congruently, inactivation of sulfurtransferase (3MST) accounts for most H2Sproductionin cydD renders cells resistant to hydrogen peroxide and to amino- E. coli grown in rich media (15). Cytoplasmic AspC and 3MST, glycoside antibiotics. In contrast, induction of cydDC sensitizes which are constitutively expressed, utilize L-cysteine as their pri- cells to oxidative stress and aminoglycosides, which can be sup- mary substrate, helping to maintain its concentration at nontoxic pressed by eamA overexpression. Furthermore, inactivation of the levels under normal growth and stress conditions (15–17). Volatile fur) cydDC tcyP ferric uptake regulator ( in Ptet- or Ptet- cells results and freely diffusible 3MST-derived H2S can be readily detected in in dramatic loss of survival, whereas catalase (katG) overexpres- a growing culture. We used this quantitative measurement of in- sion suppresses the hypersensitivity of both strains to H2O2. tracellular L-cysteine to study the role of CydDC in the L-cysteine/ These results establish CydDC as a reducer of cytoplasmic cys- cystine shuttle system and its impact on cellular resistance to tine, as opposed to an L-cysteine exporter, and further elucidate a oxidative stress and antibiotics. link between oxidative stress, antibiotic resistance, and sulfur metabolism. Significance bacteria | oxidative stress | L-cysteine | aminoglycosides | cytochrome The CydDC complex is involved in the assembly of cytochrome bd-I, a terminal oxidase of the respiratory chain required for -cysteine is an essential building block and source of redox- growth under low oxygen conditions. It has been suggested Lactive sulfhydryl groups for proteins, glutathione (GSH), and that CydDC shuttles excessive L-cysteine from the cytoplasm to many other biomolecules. Yet, L-cysteine is also toxic because of the periplasm, thereby maintaining bacterial redox homeosta- its ability to promote the Fenton reaction and generate damag- sis. Here, we demonstrate that the principle function of CydDC ing hydroxyl radicals (1–6). Therefore, bacterial cells maintain is in maintaining the reduced state of cytoplasmic L-cysteine, as the low level of intracellular L-cysteine by coordinating its bio- opposed to exporting L-cysteine, thereby providing an impor- synthesis, utilization, oxidation, and transport (7). Escherichia coli tcyP tcyJ, tant connection between sulfur metabolism, oxidative stress, Two L-cysteine/cystine importers, and and resistance to antibiotics. In particular, we establish the function synchronously with the L-cysteine exporter EamA (8) to critical role of cytoplasmic L-cysteine in mediating the toxicity constitute the L-cysteine/cystine shuttle system, which plays an of aminoglycosides. Thus, understanding the mechanisms that important role in oxidative stress tolerance by providing reducing control the bacterial redox state can lead to more effective equivalents to the periplasm (9). It has also been suggested that a strategies to counter bacterial resistance and tolerance. putative ABC-type transporter, CydDC, a heterodimeric compo- bd nent of cytochrome -I terminal oxidase, is involved in L-cysteine Author contributions: E.N. designed research; A.M., T.S., K.S., and M.N. performed re- efflux from the cytoplasm to the periplasm (10). Cells deficient in search; R.S. contributed new reagents/analytic tools; A.M., T.S., M.N., and R.S. analyzed cydD or cydC exhibit hypersensitivity to high concentrations of data; and E.N. wrote the paper. L-cysteine and DTT (10, 11), suggesting that CydDC could be The authors declare no competing interest. involved in periplasmic sulfhydryl homeostasis. Additional phe- This article is a PNAS Direct Submission. notypes of cydDC include temperature sensitivity and stationary Published under the PNAS license. phase arrest, which can be suppressed by exogenous reductants 1To whom correspondence may be addressed. Email: [email protected]. (12). The conclusion that CydDC exports L-cysteine and GSH to This article contains supporting information online at https://www.pnas.org/lookup/suppl/ the periplasm was based on the observation that everted membrane doi:10.1073/pnas.2007817117/-/DCSupplemental. vesicles uptake L-cysteine or GSH in an ATP- and CydDC- www.pnas.org/cgi/doi/10.1073/pnas.2007817117 PNAS Latest Articles | 1of6 Downloaded by guest on October 1, 2021 Results and Discussion Ptet-mstA (SI Appendix,Fig.S1). The level of H2SinΔcydD cells -cydDC H S Production as a Function of the L-Cysteine/Cystine Shuttle System. was approximately the same as in the control, whereas Ptet 2 B To establish the relationship between the E. coli L-cysteine/cystine cells generated more H2S (Fig. 1 ), arguing that hyperactive L shuttle system and H2SproductionweutilizedH2S-deficient cells CydDC increases, and does not decrease, the level of -cysteine in (ΔmstA) and cells carrying a chromosomal copy of mstA under a the cytoplasm. Indeed, CydDC and EamA demonstrated the op- A B strong pLtetO-1 promoter (P -mstA) that generate ∼2.5-fold posite effects on H2S production (compare Fig. 1 and ). tet -cydDC ΔeamA more H S than do wild-type (WT) cells (15) (Fig. 1A). These Moreover, a combination of Ptet with further in- 2 ΔeamA -cydDC reference strains were used as the genetic backgrounds for the creased H2Sproductionascomparedto or Ptet B construction of chromosomal deletions and Ptet versions of the alone (Fig. 1 ). principle L-cysteine/cystine shuttle genes: tcyP and eamA (SI Ap- It has been noted that the overexpression of CydDC from a pendix,TableS1). Deletion of the L-cystine importer, tcyP,low- high-copy-number plasmid does not result in the accumulation of ered H2SinWTandPtet-mstA cells, whereas the inactivation of L-cysteine in the culture medium (18), contrary to what is expected the L-cysteine exporter eamA increases H2SinWTandPtet-mstA of a putative L-cysteine exporter. Accordingly, we also failed to - cells (Fig. 1A). The contrasting effects of tcyP and eamA on H2S detect any increase of L-cysteine in the culture medium of Ptet production became even more apparent when the two genes were cydDC cells, as compared to WT cells (Fig. 1C). In contrast, cells eamA overexpressed. Ptet-eamA cells exhibited a drastic drop in H2S overexpressing EamA (Ptet- ) significantly increased the production, whereas Ptet-tcyP cells produced substantially more H2S L-cysteine concentration in the growth medium. These data argue as compared to control cells (Fig. 1A). These results demonstrate that CydDC does not export reduced thiols from the cytoplasm. that the level of MstA-derived H2S reflects the distribution of We hypothesized that CydDC elevates the level of cytoplasmic L-cysteine/cystine between the cytoplasm and periplasm and can be L-cysteine, and, hence, that of MstA-derived H2S, by stimulating used to quantitatively assess the cytoplasmic L-cysteine content. cytoplasmic cystine reduction. Indeed, deleting cydD in Ptet-tcyP cells, which overproduce the dedicated cystine importer, diminished CydDC Does Not Export L-Cysteine
Load more

Recommended publications
  • Biochemistry I Enzymes
    BIOCHEMISTRY I 3rd. Stage Lec. ENZYMES Biomedical Importance: Enzymes, which catalyze the biochemical reactions, are essential for life. They participate in the breakdown of nutrients to supply energy and chemical building blocks; the assembly of those building blocks into proteins, DNA, membranes, cells, and tissues; and the harnessing of energy to power cell motility, neural function, and muscle contraction. The vast majority of enzymes are proteins. Notable exceptions include ribosomal RNAs and a handful of RNA molecules imbued with endonuclease or nucleotide ligase activity known collectively as ribozymes. The ability to detect and to quantify the activity of specific enzymes in blood, other tissue fluids, or cell extracts provides information that complements the physician’s ability to diagnose and predict the prognosis of many diseases. Further medical applications include changes in the quantity or in the catalytic activity of key enzymes that can result from genetic defects, nutritional deficits, tissue damage, toxins, or infection by viral or bacterial pathogens (eg, Vibrio cholerae). Medical scientists address imbalances in enzyme activity by using pharmacologic agents to inhibit specific enzymes and are investigating gene therapy as a means to remedy deficits in enzyme level or function. In addition to serving as the catalysts for all metabolic processes, their impressive catalytic activity, substrate specificity, and stereospecificity enable enzymes to fulfill key roles in additional processes related to human health and well-being. Proteases and amylases augment the capacity of detergents to remove dirt and stains, and enzymes play important roles in producing or enhancing the nutrient value of food products for both humans and animals.
    [Show full text]
  • The Intracellular Ratio of Cysteine and Cystine in Various Tissues
    Biochem. J. (1967) 105, 891 891 Printed in Great Britain The Intracellular Ratio of Cysteine and Cystine in Various Tissues By J. C. CRAWHALL* AND S. SEGALt Clinical Endocrinology Branch, National In8titute of Arthriti8 and Metabolic Di8ease8, National Institute8 of Health, Bethe8da, Md., U.S.A. (Received 20 February 1967) 1. The cysteine-cystine ratio was measured in rat kidney cortex, diaphragm, jejunum, liver and brain. 2. This ratio was determined by incubating these tissues in buffer containing [35S]cystine and then homogenizing the tissue in a buffered solution of N-ethyhnaleimide. The products of this reaction were separated by high-voltage electrophoresis and the radioactivity in the cystine and 2-(L-2'-amino- 2'-carboxyethylthio)-N-ethylsuccinimide regions was determined. 3. In these tissues cyst(e)ine was mainly present in the reduced form. 4. After incubation of [35S]cystine with rat jejunal segments it was found that 36% of the cystine in the medium has been reduced. 5. Anaerobiosis, Na+-free media, glucose and high concentrations of cystine and lysine were found not to affect significantly the cysteine-cystine ratio in rat kidney-cortex slices. Numerous studies of the kinetics of amino acid The method of measuring cystine-cysteine ratios transport into various tissues in vitro have been described in this paper has been designed to remove described. One of the requirements of this type of all the cellular enzyme activity as rapidly as study with radioactive isotopically labelled amino possible at the end ofthe tissue incubation period by acids is that the radioactivity measured within the precipitation of the enzymes with trichloroacetic tissue corresponds to the amino acid being studied acid.
    [Show full text]
  • The Cysteine Proteome 13 N Q114 Young-Mi Go, Joshua D
    Free Radical Biology and Medicine ∎ (∎∎∎∎) ∎∎∎–∎∎∎ 1 Contents lists available at ScienceDirect 2 3 4 Free Radical Biology and Medicine 5 6 journal homepage: www.elsevier.com/locate/freeradbiomed 7 8 9 Review Article 10 11 12 The cysteine proteome 13 n Q114 Young-Mi Go, Joshua D. Chandler, Dean P. Jones 15 Division of Pulmonary, Allergy and Critical Care Medicine, Department of Medicine, Emory University, Atlanta, GA 30322, USA 16 17 18 article info abstract 19 20 Article history: The cysteine (Cys) proteome is a major component of the adaptive interface between the genome and 21 Received 17 November 2014 the exposome. The thiol moiety of Cys undergoes a range of biologic modifications enabling biological 22 Received in revised form switching of structure and reactivity. These biological modifications include sulfenylation and disulfide 23 17 March 2015 formation, formation of higher oxidation states, S-nitrosylation, persulfidation, metalation, and other Accepted 22 March 2015 24 modifications. Extensive knowledge about these systems and their compartmentalization now provides 25 a foundation to develop advanced integrative models of Cys proteome regulation. In particular, detailed Keywords: 26 understanding of redox signaling pathways and sensing networks is becoming available to allow the Cysteine proteome discrimination of network structures. This research focuses attention on the need for atlases of Cys 27 Redox proteome modifications to develop systems biology models. Such atlases will be especially useful for integrative 28 Redox signaling studies linking the Cys proteome to imaging and other omics platforms, providing a basis for improved 29 Functional network Thiol redox-based therapeutics. Thus, a framework is emerging to place the Cys proteome as a complement to 30 Free radicals the quantitative proteome in the omics continuum connecting the genome to the exposome.
    [Show full text]
  • Metabolic Regulation of Ferroptosis in Cancer
    biology Review Metabolic Regulation of Ferroptosis in Cancer Min Ji Kim 1,2,† , Greg Jiho Yun 1,2,† and Sung Eun Kim 1,2,* 1 Department of Biosystems and Biomedical Sciences, College of Health Sciences, Korea University, Seoul 305-350, Korea; [email protected] (M.J.K.); [email protected] (G.J.Y.) 2 Department of Integrated Biomedical and Life Sciences, College of Health Sciences, Korea University, Seoul 305-350, Korea * Correspondence: [email protected]; Tel.: +82-2-3290-5647 † These authors contributed equally to this work as co-first authors. Simple Summary: Ferroptosis is a recently defined nonapoptotic form of cell death that is associated with various human diseases, including cancer. As ferroptosis is caused by an overdose of lipid peroxidation resulting from dysregulation of the cellular antioxidant system, it is inherently closely associated with cellular metabolism. Here, we provide an updated review of the recent studies that have shown mechanisms of metabolic regulation of ferroptosis in the context of cancer. Abstract: Ferroptosis is a unique cell death mechanism that is executed by the excessive accumulation of lipid peroxidation in cells. The relevance of ferroptosis in multiple human diseases such as neurodegeneration, organ damage, and cancer is becoming increasingly evident. As ferroptosis is deeply intertwined with metabolic pathways such as iron, cyst(e)ine, glutathione, and lipid metabolism, a better understanding of how ferroptosis is regulated by these pathways will enable the precise utilization or prevention of ferroptosis for therapeutic uses. In this review, we present an update of the mechanisms underlying diverse metabolic pathways that can regulate ferroptosis in cancer.
    [Show full text]
  • Molecular Basis for Redox Control by the Human Cystine/Glutamate Antiporter
    bioRxiv preprint doi: https://doi.org/10.1101/2021.08.09.455631; this version posted August 9, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. It is made available under aCC-BY 4.0 International license. Molecular basis for redox control by the human cystine/glutamate antiporter System xc-. Joanne L. Parker1, *, #, Justin C. Deme2,3,4#, Dimitrios Kolokouris1, Gabriel Kuteyi1, Philip C. Biggin1, Susan M. Lea2,3,4 *, Simon Newstead1,5*. 1Department of Biochemistry, University of Oxford, Oxford, OX1 3QU, UK; 2Dunn School of Pathology, University of Oxford, Oxford, OX1 3RE, 3 Central Oxford Structural Molecular Imaging Centre, University of Oxford, South Parks Road, Oxford, OX1 3RE, 4Center for Structural Biology, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA, 5The Kavli Institute for Nanoscience Discovery, University of Oxford, Oxford, OX1 3QU, UK. Cysteine plays an essential role in cellular redox homeostasis as a key constituent of the tripeptide glutathione (GSH). A rate limiting step in cellular GSH synthesis is the availability of cysteine. However, circulating cysteine exists in the blood as the oxidised di-peptide cystine, requiring specialised transport systems for its import into the cell. System xc- is a dedicated cystine transporter, importing cystine in exchange for intracellular glutamate. To counteract elevated levels of reactive oxygen species in cancerous cells system xc- is frequently upregulated, making it an attractive target for anticancer therapies. However, the molecular basis for ligand recognition remains elusive, hampering efforts to specifically target this transport system.
    [Show full text]
  • O O2 Enzymes Available from Sigma Enzymes Available from Sigma
    COO 2.7.1.15 Ribokinase OXIDOREDUCTASES CONH2 COO 2.7.1.16 Ribulokinase 1.1.1.1 Alcohol dehydrogenase BLOOD GROUP + O O + O O 1.1.1.3 Homoserine dehydrogenase HYALURONIC ACID DERMATAN ALGINATES O-ANTIGENS STARCH GLYCOGEN CH COO N COO 2.7.1.17 Xylulokinase P GLYCOPROTEINS SUBSTANCES 2 OH N + COO 1.1.1.8 Glycerol-3-phosphate dehydrogenase Ribose -O - P - O - P - O- Adenosine(P) Ribose - O - P - O - P - O -Adenosine NICOTINATE 2.7.1.19 Phosphoribulokinase GANGLIOSIDES PEPTIDO- CH OH CH OH N 1 + COO 1.1.1.9 D-Xylulose reductase 2 2 NH .2.1 2.7.1.24 Dephospho-CoA kinase O CHITIN CHONDROITIN PECTIN INULIN CELLULOSE O O NH O O O O Ribose- P 2.4 N N RP 1.1.1.10 l-Xylulose reductase MUCINS GLYCAN 6.3.5.1 2.7.7.18 2.7.1.25 Adenylylsulfate kinase CH2OH HO Indoleacetate Indoxyl + 1.1.1.14 l-Iditol dehydrogenase L O O O Desamino-NAD Nicotinate- Quinolinate- A 2.7.1.28 Triokinase O O 1.1.1.132 HO (Auxin) NAD(P) 6.3.1.5 2.4.2.19 1.1.1.19 Glucuronate reductase CHOH - 2.4.1.68 CH3 OH OH OH nucleotide 2.7.1.30 Glycerol kinase Y - COO nucleotide 2.7.1.31 Glycerate kinase 1.1.1.21 Aldehyde reductase AcNH CHOH COO 6.3.2.7-10 2.4.1.69 O 1.2.3.7 2.4.2.19 R OPPT OH OH + 1.1.1.22 UDPglucose dehydrogenase 2.4.99.7 HO O OPPU HO 2.7.1.32 Choline kinase S CH2OH 6.3.2.13 OH OPPU CH HO CH2CH(NH3)COO HO CH CH NH HO CH2CH2NHCOCH3 CH O CH CH NHCOCH COO 1.1.1.23 Histidinol dehydrogenase OPC 2.4.1.17 3 2.4.1.29 CH CHO 2 2 2 3 2 2 3 O 2.7.1.33 Pantothenate kinase CH3CH NHAC OH OH OH LACTOSE 2 COO 1.1.1.25 Shikimate dehydrogenase A HO HO OPPG CH OH 2.7.1.34 Pantetheine kinase UDP- TDP-Rhamnose 2 NH NH NH NH N M 2.7.1.36 Mevalonate kinase 1.1.1.27 Lactate dehydrogenase HO COO- GDP- 2.4.1.21 O NH NH 4.1.1.28 2.3.1.5 2.1.1.4 1.1.1.29 Glycerate dehydrogenase C UDP-N-Ac-Muramate Iduronate OH 2.4.1.1 2.4.1.11 HO 5-Hydroxy- 5-Hydroxytryptamine N-Acetyl-serotonin N-Acetyl-5-O-methyl-serotonin Quinolinate 2.7.1.39 Homoserine kinase Mannuronate CH3 etc.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0275279 A1 Rozzell Et Al
    US 20060275279A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0275279 A1 ROZZell et al. (43) Pub. Date: Dec. 7, 2006 (54) METHODS FOR DISSOLVING CYSTINE (22) Filed: Jun. 6, 2005 STONES AND REDUCING CYSTINE IN URINE Publication Classification (76) Inventors: J. David Rozzell, Burbank, CA (US); (51) Int. Cl. Kavitha Vedha-Peters, Pasadena, CA A6II 38MSI (2006.01) (US) (52) U.S. Cl. ............................................................ 424/94.5 Correspondence Address: CHRISTIE, PARKER & HALE, LLP (57) ABSTRACT PO BOX 7O68 PASADENA, CA 91109–7068 (US) The present invention is directed to an improved method of treating cystinuria, utilizing the catalytic ability of cystinase (21) Appl. No.: 11/146,551 to increase the rate of cystine Stone dissolution. Patent Application Publication Dec. 7, 2006 Sheet 1 of 4 US 2006/0275279 A1 Hs1N1 Ncoh L-Homocysteine -- H2 O HOC n1ns 1-1N CO2H Cystathionine?3-lyase ls CO2H H2 Pyruvate L-Cystathionine H NH FIG. 1. Metabolic Reaction Catalyzed by Cystathionine-?s-Lyase Patent Application Publication Dec. 7, 2006 Sheet 2 of 4 US 2006/0275279 A1 NH2 Hs1 S Y1Ncoh L-Thiocysteine -- NH2 O Hozen-1- 1N1 no H Cystathionine e i 2 B-lyase CO2H NH2 P L-CystineA- y ruvate -- NH FIG. 2. "Un-Natural" Reaction Catalyzed by Cystathionine-?s-Lyase on L-Cystine Patent Application Publication Dec. 7, 2006 Sheet 3 of 4 US 2006/0275279 A1 Dissolution of Cystine Stones with Cystathionine beta-lyase (MetC) s -o-control (no MetC) al -H 1 mg/mL MetC g - 5 mg/mL MetC 3. -- 10 mg/mL MetC S.
    [Show full text]
  • Redox Homeostatis and Stress in Mouse Livers Lacking the Nadph
    REDOX HOMEOSTASIS AND STRESS IN MOUSE LIVERS LACKING THE NADPH-DEPENDENT DISULFIDE REDUCTASE SYSTEMS by Colin Gregory Miller A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Chemistry MONTANA STATE UNIVERSITY Bozeman, Montana November 2019 ©COPYRIGHT by Colin Gregory Miller 2019 All Rights Reserved ii DEDICATION I would like to dedicate this thesis to my dear friends Adrienne Arnold, Jacob Artz, Aoife Casey, Michael Christman, Phil Hartman, Ky Mickelsen, Sarah Partovi, Greg Prussia and Danica Walsh. Your support has been indescribably generous and completely invaluable. My quality of life, especially during graduate school, has been immeasurably improved by you all and I count myself incredibly lucky to call you my friends and colleagues. Most importantly, I would like to dedicate this degree to my mom. Any standard of excellence I have ever held has been inspired by you. Your compassion and generosity to others, your unwavering positivity and resilience are a constant source of inspiration. I would consider myself a complete success if I grow up to be half the person you are. iii ACKNOWLEDGEMENTS First, I would like to acknowledge support for the work presented in this thesis provided by the NIH (AG055022) and Montana State University. I would also like to acknowledge committee members Dr. Mary Cloninger and Dr. Brian Bothner for invaluable scientific support and guidance. I would like to thank Dr. Loretta Dorn, Dr. James Hohman and the Chemistry Department of Fort Hays State University for providing me the training and desire to pursue a life in science.
    [Show full text]
  • Cysteine: an Overlooked Energy and Carbon Source
    www.nature.com/scientificreports OPEN Cysteine: an overlooked energy and carbon source Luise Göbbels1, Anja Poehlein2, Albert Dumnitch1, Richard Egelkamp2, Cathrin Kröger1, Johanna Haerdter3, Thomas Hackl3, Artur Feld4, Horst Weller4, Rolf Daniel2, Wolfgang R. Streit1 & Marie Charlotte Schoelmerich1* Biohybrids composed of microorganisms and nanoparticles have emerged as potential systems for bioenergy and high-value compound production from CO2 and light energy, yet the cellular and metabolic processes within the biological component of this system are still elusive. Here we dissect the biohybrid composed of the anaerobic acetogenic bacterium Moorella thermoacetica and cadmium sulphide nanoparticles (CdS) in terms of physiology, metabolism, enzymatics and transcriptomic profling. Our analyses show that while the organism does not grow on l-cysteine, it is metabolized to acetate in the biohybrid system and this metabolism is independent of CdS or light. CdS cells have higher metabolic activity, despite an inhibitory efect of Cd2+ on key enzymes, because of an intracellular storage compound linked to arginine metabolism. We identify diferent routes how cysteine and its oxidized form can be innately metabolized by the model acetogen and what intracellular mechanisms are triggered by cysteine, cadmium or blue light. Anaerobic microorganisms play a pivotal role in the global cycling of elements and nutrients, are key in determin- ing the health of animals and humans and are important players for biotechnological and industrial processes to solve tomorrow’s challenges of pollution, resource scarcity and energy requirements 1,2. An innovative proof-of- concept study has recently been described in which a non-photosynthetic anaerobic bacterium becomes photo- synthetic by coupling it to CdS nanoparticles3.
    [Show full text]
  • Molecular Mechanism and Metabolic Function of the S
    MOLECULAR MECHANISM AND METABOLIC FUNCTION OF THE S- NITROSO-COENZYME A REDUCTASE AKR1A1 by COLIN T. STOMBERSKI Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy Dissertation Advisor: Jonathan S. Stamler Department of Biochemistry CASE WESTERN RESERVE UNIVERSITY May, 2019 CASE WESTERN RESERVE UNIVERSITY SCHOOL OF GRADUATE STUDIES We hereby approve the dissertation of COLIN T. STOMBERSKI candidate for the degree of Doctor of Philosophy*. Committee Chair Focco van den Akker Committee Members Jonathan Stamler George Dubyak Mukesh Jain Hung-Ying Kao 03-22-2019 *We also certify that written approval has been obtained for any proprietary material contained therein TABLE OF CONTENTS Table of Contents ………………………………………………………………………… i List of Tables ……………………………………………………………………………. v List of Figures ………………………………………………………………………….. vi List of Abbreviations …………………………………………………………………… ix Acknowledgements …………………………………………………………………….. xi Abstract ………………………………………………………………………………….. 1 Foundation and Experimental Framework ……………………………………………….. 3 Chapter 1: Protein S-nitrosylation: Determinants of specificity and enzymatic regulation of S-nitrosothiol-based signaling …………………………………………….. 5 1.1 Introduction …………………………………………………………………. 6 1.2 S-nitrosothiol specificity …………………………………………………….. 8 1.2.1 Acid-base and hydrophobic motifs ……………………………… 9 1.2.2 Interaction with nitric oxide synthases ………………………….. 13 1.3 S-nitrosothiol stability and reactivity ……………………………………….. 15 1.3.1 RSNO bond chemistry ………………………………………….. 16 1.3.2 Protein SNO—thiol reaction bias ………………………………. 18 1.3.3 SNO sites do not overlap S-oxidation sites …………………….. 19 1.4 Enzymatic denitrosylation ………………………………………………….. 20 1.4.1 The thioredoxin system ………………………………………… 21 1.4.2 LMW-SNO reductases …………………………………………. 23 1.4.3 The GSNO reductase system …………………………………… 24 1.4.4 GSNOR in physiology and pathophysiology …………………… 26 i 1.4.5 The SNO-CoA reductase system ……………………………….. 31 1.5 Specificity in denitrosylation ……………………………………………….
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur Et Al
    US 2012026.6329A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2012/0266329 A1 Mathur et al. (43) Pub. Date: Oct. 18, 2012 (54) NUCLEICACIDS AND PROTEINS AND CI2N 9/10 (2006.01) METHODS FOR MAKING AND USING THEMI CI2N 9/24 (2006.01) CI2N 9/02 (2006.01) (75) Inventors: Eric J. Mathur, Carlsbad, CA CI2N 9/06 (2006.01) (US); Cathy Chang, San Marcos, CI2P 2L/02 (2006.01) CA (US) CI2O I/04 (2006.01) CI2N 9/96 (2006.01) (73) Assignee: BP Corporation North America CI2N 5/82 (2006.01) Inc., Houston, TX (US) CI2N 15/53 (2006.01) CI2N IS/54 (2006.01) CI2N 15/57 2006.O1 (22) Filed: Feb. 20, 2012 CI2N IS/60 308: Related U.S. Application Data EN f :08: (62) Division of application No. 1 1/817,403, filed on May AOIH 5/00 (2006.01) 7, 2008, now Pat. No. 8,119,385, filed as application AOIH 5/10 (2006.01) No. PCT/US2006/007642 on Mar. 3, 2006. C07K I4/00 (2006.01) CI2N IS/II (2006.01) (60) Provisional application No. 60/658,984, filed on Mar. AOIH I/06 (2006.01) 4, 2005. CI2N 15/63 (2006.01) Publication Classification (52) U.S. Cl. ................... 800/293; 435/320.1; 435/252.3: 435/325; 435/254.11: 435/254.2:435/348; (51) Int. Cl. 435/419; 435/195; 435/196; 435/198: 435/233; CI2N 15/52 (2006.01) 435/201:435/232; 435/208; 435/227; 435/193; CI2N 15/85 (2006.01) 435/200; 435/189: 435/191: 435/69.1; 435/34; CI2N 5/86 (2006.01) 435/188:536/23.2; 435/468; 800/298; 800/320; CI2N 15/867 (2006.01) 800/317.2: 800/317.4: 800/320.3: 800/306; CI2N 5/864 (2006.01) 800/312 800/320.2: 800/317.3; 800/322; CI2N 5/8 (2006.01) 800/320.1; 530/350, 536/23.1: 800/278; 800/294 CI2N I/2 (2006.01) CI2N 5/10 (2006.01) (57) ABSTRACT CI2N L/15 (2006.01) CI2N I/19 (2006.01) The invention provides polypeptides, including enzymes, CI2N 9/14 (2006.01) structural proteins and binding proteins, polynucleotides CI2N 9/16 (2006.01) encoding these polypeptides, and methods of making and CI2N 9/20 (2006.01) using these polynucleotides and polypeptides.
    [Show full text]
  • All Enzymes in BRENDA™ the Comprehensive Enzyme Information System
    All enzymes in BRENDA™ The Comprehensive Enzyme Information System http://www.brenda-enzymes.org/index.php4?page=information/all_enzymes.php4 1.1.1.1 alcohol dehydrogenase 1.1.1.B1 D-arabitol-phosphate dehydrogenase 1.1.1.2 alcohol dehydrogenase (NADP+) 1.1.1.B3 (S)-specific secondary alcohol dehydrogenase 1.1.1.3 homoserine dehydrogenase 1.1.1.B4 (R)-specific secondary alcohol dehydrogenase 1.1.1.4 (R,R)-butanediol dehydrogenase 1.1.1.5 acetoin dehydrogenase 1.1.1.B5 NADP-retinol dehydrogenase 1.1.1.6 glycerol dehydrogenase 1.1.1.7 propanediol-phosphate dehydrogenase 1.1.1.8 glycerol-3-phosphate dehydrogenase (NAD+) 1.1.1.9 D-xylulose reductase 1.1.1.10 L-xylulose reductase 1.1.1.11 D-arabinitol 4-dehydrogenase 1.1.1.12 L-arabinitol 4-dehydrogenase 1.1.1.13 L-arabinitol 2-dehydrogenase 1.1.1.14 L-iditol 2-dehydrogenase 1.1.1.15 D-iditol 2-dehydrogenase 1.1.1.16 galactitol 2-dehydrogenase 1.1.1.17 mannitol-1-phosphate 5-dehydrogenase 1.1.1.18 inositol 2-dehydrogenase 1.1.1.19 glucuronate reductase 1.1.1.20 glucuronolactone reductase 1.1.1.21 aldehyde reductase 1.1.1.22 UDP-glucose 6-dehydrogenase 1.1.1.23 histidinol dehydrogenase 1.1.1.24 quinate dehydrogenase 1.1.1.25 shikimate dehydrogenase 1.1.1.26 glyoxylate reductase 1.1.1.27 L-lactate dehydrogenase 1.1.1.28 D-lactate dehydrogenase 1.1.1.29 glycerate dehydrogenase 1.1.1.30 3-hydroxybutyrate dehydrogenase 1.1.1.31 3-hydroxyisobutyrate dehydrogenase 1.1.1.32 mevaldate reductase 1.1.1.33 mevaldate reductase (NADPH) 1.1.1.34 hydroxymethylglutaryl-CoA reductase (NADPH) 1.1.1.35 3-hydroxyacyl-CoA
    [Show full text]